<p>Berger Financial Group Inc 在最近向证券交易委员会的披露中表示，在第三季度将其在艾伯维公司（NYSE:ABBV - 免费报告）的股份增加了 41.2%。该公司在此期间额外购买了 5,838 股后，持有 20,025 股该公司的股票。根据其最近的 SEC 文件，Berger Financial Group Inc 在艾伯维的持股价值为 4,637,000 美元。</p>
<ul>
<li>3 只分析师看好的 2026 年股息增长股票</li>
</ul>
<p>其他对冲基金和机构投资者也买卖了该公司的股票。Hobart Private Capital LLC 在第三季度将其在艾伯维的持股增加了 4.4%。Hobart Private Capital LLC 现在拥有 1,127 股该公司的股票，价值 261,000 美元，此前在上个季度额外购买了 48 股。Rise Advisors LLC 在第三季度将其在艾伯维的持股增加了 3.4%。Rise Advisors LLC 现在拥有 1,451 股该公司的股票，价值 336,000 美元，此前在上个季度额外购买了 48 股。Sivia Capital Partners LLC 在第二季度将其在艾伯维的持股增加了 1.1%。Sivia Capital Partners LLC 现在拥有 4,571 股该公司的股票，价值 848,000 美元，此前在上个季度额外购买了 51 股。FF Advisors LLC 在第二季度将其在艾伯维的持股增加了 3.6%。FF Advisors LLC 现在拥有 1,539 股该公司的股票，价值 286,000 美元，此前在上个季度额外购买了 53 股。最后，Landaas &amp; Co. WI ADV 在第二季度将其在艾伯维的持股增加了 1.1%。Landaas &amp; Co. WI ADV 现在拥有 4,955 股该公司的股票，价值 920,000 美元，此前在上个季度额外购买了 53 股。机构投资者和对冲基金持有该公司 70.23% 的股票。</p>
<h2>艾伯维股票表现</h2>
<p>艾伯维的股票在周二开盘价为 227.82 美元。该公司的债务与股本比率为 44.14，速动比率为 0.60，流动比率为 0.72。艾伯维公司的 52 周最低价为 164.39 美元，52 周最高价为 244.81 美元。该公司的市值为 4026.4 亿美元，市盈率为 172.59，市盈增长比率为 1.29，贝塔值为 0.36。该公司的 50 日移动平均线为 226.58 美元，200 日移动平均线为 211.60 美元。</p>
<ul>
<li>股息强者：3 只为长期投资而生的蓝筹股</li>
</ul>
<p>艾伯维（NYSE:ABBV - 获取免费报告）最近在 10 月 31 日（星期五）发布了季度财报。该公司报告季度每股收益为 1.86 美元，超出分析师一致预期的 1.77 美元，超出幅度为 0.09 美元。该公司在本季度的收入为 157.8 亿美元，而一致预期为 155.8 亿美元。艾伯维的股本回报率为 3,216.47%，净利润率为 4.00%。与去年同期相比，艾伯维本季度的收入增长了 9.1%。在去年同期，该公司每股收益为 3.00 美元。艾伯维已将其 2025 年第四季度的指导目标设定为 3.320-3.360 每股收益。卖方分析师预计艾伯维公司本财年的每股收益将达到 12.31 美元。</p>
<h2>艾伯维增加股息</h2>
<p>该公司还最近宣布了一项季度股息，将于 2 月 17 日（星期二）支付。1 月 16 日（星期五）的股东将获得每股 1.73 美元的股息。除息日期为 1 月 16 日（星期五）。这比艾伯维之前的季度股息 1.64 美元有所增加。这代表着每年 6.92 美元的股息，收益率为 3.0%。艾伯维的股息支付比率目前为 496.97%。</p>
<h2>华尔街分析师预测增长</h2>
<ul>
<li>HIMS 经历了过山车般的旅程。投资者应该加入吗？</li>
</ul>
<p>多家券商对艾伯维发表了评论。Weiss Ratings 在 10 月 8 日（星期三）的研究报告中重申了对艾伯维股票的 “持有（c）” 评级。富国银行将艾伯维股票的目标价从 240.00 美元上调至 260.00 美元，并在 9 月 12 日（星期五）的研究报告中给予该股 “超配” 评级。Raymond James Financial 在 11 月 3 日（星期一）的研究报告中设定了艾伯维股票的目标价为 256.00 美元。汇丰银行将艾伯维的评级从 “持有” 上调至 “买入”，并在 12 月 10 日（星期三）的报告中将该股的目标价从 225.00 美元上调至 265.00 美元。最后，汇丰全球研究在 12 月 10 日（星期三）的研究报告中将艾伯维的评级从 “持有” 上调至 “强烈买入”。三位股票研究分析师对该股给予了强烈买入评级，十三位给予了买入评级，八位给予了持有评级。根据 MarketBeat 的数据，艾伯维目前的共识评级为 “适度买入”，共识目标价为 245.84 美元。</p>
<p><strong>阅读我们对艾伯维的最新分析</strong></p>
<h2>关于艾伯维</h2>
<p>（免费报告）</p>
<p>艾伯维是一家全球性的、以研究为驱动的生物制药公司，于 2013 年从雅培实验室分拆而成，总部位于伊利诺伊州北芝加哥。该公司专注于发现、开发和商业化针对复杂且常常是慢性医疗条件的治疗方案。其业务涵盖研究与开发、制造、监管事务和商业化，重点是将专业药物推向多个治疗领域的市场。</p>
<p>艾伯维的产品组合和研发管道涵盖多个主要治疗类别，包括免疫学、肿瘤学、神经科学、病毒学和女性健康。</p>
<h2>另见</h2>
<ul>
<li>五只我们更看好的股票比艾伯维更好</li>
<li>请勿删除，立即阅读</li>
<li>投资者警报：微型 “3 美元人工智能奇迹股票” 即将爆发</li>
<li>是否可以从资本利得税中扣除任何费用？</li>
<li>巴菲特、盖茨和贝索斯悄然抛售股票——原因在这里</li>
<li>最后的黄金牛市</li>
</ul>
<p><strong>想看看其他对冲基金持有的艾伯维股票吗？</strong> 请访问 HoldingsChannel.com 获取艾伯维公司（NYSE:ABBV - 免费报告）的最新 13F 文件和内部交易信息。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFCQlY?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFCQlY"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在艾伯维吗？</h2>
<p>在考虑艾伯维之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而艾伯维并不在名单上。</p>
<p>虽然艾伯维目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

艾伯维

<p>Berger Financial Group Inc 在第三季度将其在艾伯维（AbbVie Inc）的持股增加了 41.2%，目前持有 20,025 股，价值 464 万美元。其他机构投资者也调整了在艾伯维的持仓。该公司报告了强劲的季度收益，营收同比增长 9.1%，每股股息提高至 1.73 美元。分析师们给予了积极的评级，一些分析师将艾伯维的股票评级上调至 “买入” 或 “强力买入”</p>

<p>Berger Financial Group Inc increased its stake in shares of AbbVie Inc. (NYSE:ABBV - Free Report) by 41.2% during the third quarter, according to the company in its most recent disclosure with the Securities &amp; Exchange Commission. The firm owned 20,025 shares of the company's stock after acquiring an additional 5,838 shares during the period. Berger Financial Group Inc's holdings in AbbVie were worth $4,637,000 as of its most recent SEC filing.</p>
<div class="lb-trans"><p>Berger Financial Group Inc 在最近向证券交易委员会的披露中表示，在第三季度将其在艾伯维公司（NYSE:ABBV - 免费报告）的股份增加了 41.2%。该公司在此期间额外购买了 5,838 股后，持有 20,025 股该公司的股票。根据其最近的 SEC 文件，Berger Financial Group Inc 在艾伯维的持股价值为 4,637,000 美元。</p>
</div><ul>
<li>3 Dividend Growth Stocks Analysts Are Upgrading for 2026</li>
</ul>
<div class="lb-trans"><ul>
<li>3 只分析师看好的 2026 年股息增长股票</li>
</ul>
</div><p>Other hedge funds and other institutional investors have also bought and sold shares of the company. Hobart Private Capital LLC raised its holdings in shares of AbbVie by 4.4% in the third quarter. Hobart Private Capital LLC now owns 1,127 shares of the company's stock valued at $261,000 after purchasing an additional 48 shares during the last quarter. Rise Advisors LLC grew its position in AbbVie by 3.4% in the third quarter. Rise Advisors LLC now owns 1,451 shares of the company's stock valued at $336,000 after purchasing an additional 48 shares in the last quarter. Sivia Capital Partners LLC increased its position in shares of AbbVie by 1.1% in the second quarter. Sivia Capital Partners LLC now owns 4,571 shares of the company's stock valued at $848,000 after acquiring an additional 51 shares during the last quarter. FF Advisors LLC grew its stake in AbbVie by 3.6% in the second quarter. FF Advisors LLC now owns 1,539 shares of the company's stock valued at $286,000 after purchasing an additional 53 shares in the last quarter. Finally, Landaas &amp; Co. WI ADV grew its stake in AbbVie by 1.1% in the second quarter. Landaas &amp; Co. WI ADV now owns 4,955 shares of the company's stock valued at $920,000 after purchasing an additional 53 shares in the last quarter. Institutional investors and hedge funds own 70.23% of the company's stock.</p>
<div class="lb-trans"><p>其他对冲基金和机构投资者也买卖了该公司的股票。Hobart Private Capital LLC 在第三季度将其在艾伯维的持股增加了 4.4%。Hobart Private Capital LLC 现在拥有 1,127 股该公司的股票，价值 261,000 美元，此前在上个季度额外购买了 48 股。Rise Advisors LLC 在第三季度将其在艾伯维的持股增加了 3.4%。Rise Advisors LLC 现在拥有 1,451 股该公司的股票，价值 336,000 美元，此前在上个季度额外购买了 48 股。Sivia Capital Partners LLC 在第二季度将其在艾伯维的持股增加了 1.1%。Sivia Capital Partners LLC 现在拥有 4,571 股该公司的股票，价值 848,000 美元，此前在上个季度额外购买了 51 股。FF Advisors LLC 在第二季度将其在艾伯维的持股增加了 3.6%。FF Advisors LLC 现在拥有 1,539 股该公司的股票，价值 286,000 美元，此前在上个季度额外购买了 53 股。最后，Landaas &amp; Co. WI ADV 在第二季度将其在艾伯维的持股增加了 1.1%。Landaas &amp; Co. WI ADV 现在拥有 4,955 股该公司的股票，价值 920,000 美元，此前在上个季度额外购买了 53 股。机构投资者和对冲基金持有该公司 70.23% 的股票。</p>
</div><h2>AbbVie Stock Performance</h2>
<div class="lb-trans"><h2>艾伯维股票表现</h2>
</div><p>ABBV opened at $227.82 on Tuesday. The company has a debt-to-equity ratio of 44.14, a quick ratio of 0.60 and a current ratio of 0.72. AbbVie Inc. has a 52-week low of $164.39 and a 52-week high of $244.81. The firm has a market cap of $402.64 billion, a P/E ratio of 172.59, a price-to-earnings-growth ratio of 1.29 and a beta of 0.36. The business's fifty day moving average is $226.58 and its 200-day moving average is $211.60.</p>
<div class="lb-trans"><p>艾伯维的股票在周二开盘价为 227.82 美元。该公司的债务与股本比率为 44.14，速动比率为 0.60，流动比率为 0.72。艾伯维公司的 52 周最低价为 164.39 美元，52 周最高价为 244.81 美元。该公司的市值为 4026.4 亿美元，市盈率为 172.59，市盈增长比率为 1.29，贝塔值为 0.36。该公司的 50 日移动平均线为 226.58 美元，200 日移动平均线为 211.60 美元。</p>
</div><ul>
<li>Dividend Powerhouses: 3 Blue-Chip Stocks Built for the Long Haul</li>
</ul>
<div class="lb-trans"><ul>
<li>股息强者：3 只为长期投资而生的蓝筹股</li>
</ul>
</div><p>AbbVie (NYSE:ABBV - Get Free Report) last posted its quarterly earnings results on Friday, October 31st. The company reported $1.86 EPS for the quarter, beating analysts' consensus estimates of $1.77 by $0.09. The business had revenue of $15.78 billion during the quarter, compared to the consensus estimate of $15.58 billion. AbbVie had a return on equity of 3,216.47% and a net margin of 4.00%.AbbVie's revenue for the quarter was up 9.1% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $3.00 earnings per share. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. Sell-side analysts expect that AbbVie Inc. will post 12.31 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>艾伯维（NYSE:ABBV - 获取免费报告）最近在 10 月 31 日（星期五）发布了季度财报。该公司报告季度每股收益为 1.86 美元，超出分析师一致预期的 1.77 美元，超出幅度为 0.09 美元。该公司在本季度的收入为 157.8 亿美元，而一致预期为 155.8 亿美元。艾伯维的股本回报率为 3,216.47%，净利润率为 4.00%。与去年同期相比，艾伯维本季度的收入增长了 9.1%。在去年同期，该公司每股收益为 3.00 美元。艾伯维已将其 2025 年第四季度的指导目标设定为 3.320-3.360 每股收益。卖方分析师预计艾伯维公司本财年的每股收益将达到 12.31 美元。</p>
</div><h2>AbbVie Increases Dividend</h2>
<div class="lb-trans"><h2>艾伯维增加股息</h2>
</div><p>The firm also recently announced a quarterly dividend, which will be paid on Tuesday, February 17th. Shareholders of record on Friday, January 16th will be paid a dividend of $1.73 per share. The ex-dividend date is Friday, January 16th. This is a boost from AbbVie's previous quarterly dividend of $1.64. This represents a $6.92 annualized dividend and a yield of 3.0%. AbbVie's dividend payout ratio is currently 496.97%.</p>
<div class="lb-trans"><p>该公司还最近宣布了一项季度股息，将于 2 月 17 日（星期二）支付。1 月 16 日（星期五）的股东将获得每股 1.73 美元的股息。除息日期为 1 月 16 日（星期五）。这比艾伯维之前的季度股息 1.64 美元有所增加。这代表着每年 6.92 美元的股息，收益率为 3.0%。艾伯维的股息支付比率目前为 496.97%。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>华尔街分析师预测增长</h2>
</div><ul>
<li>HIMS Has Been a Roller Coaster Ride. Should Investors Hop On?</li>
</ul>
<div class="lb-trans"><ul>
<li>HIMS 经历了过山车般的旅程。投资者应该加入吗？</li>
</ul>
</div><p>A number of brokerages have commented on ABBV. Weiss Ratings reiterated a &#34;hold (c)&#34; rating on shares of AbbVie in a research note on Wednesday, October 8th. Wells Fargo &amp; Company lifted their price objective on shares of AbbVie from $240.00 to $260.00 and gave the stock an &#34;overweight&#34; rating in a research report on Friday, September 12th. Raymond James Financial set a $256.00 price target on shares of AbbVie in a research note on Monday, November 3rd. HSBC upgraded AbbVie from a &#34;hold&#34; rating to a &#34;buy&#34; rating and boosted their price objective for the stock from $225.00 to $265.00 in a report on Wednesday, December 10th. Finally, Hsbc Global Res upgraded AbbVie from a &#34;hold&#34; rating to a &#34;strong-buy&#34; rating in a research note on Wednesday, December 10th. Three equities research analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and eight have issued a Hold rating to the company's stock. According to data from MarketBeat, AbbVie presently has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $245.84.</p>
<div class="lb-trans"><p>多家券商对艾伯维发表了评论。Weiss Ratings 在 10 月 8 日（星期三）的研究报告中重申了对艾伯维股票的 “持有（c）” 评级。富国银行将艾伯维股票的目标价从 240.00 美元上调至 260.00 美元，并在 9 月 12 日（星期五）的研究报告中给予该股 “超配” 评级。Raymond James Financial 在 11 月 3 日（星期一）的研究报告中设定了艾伯维股票的目标价为 256.00 美元。汇丰银行将艾伯维的评级从 “持有” 上调至 “买入”，并在 12 月 10 日（星期三）的报告中将该股的目标价从 225.00 美元上调至 265.00 美元。最后，汇丰全球研究在 12 月 10 日（星期三）的研究报告中将艾伯维的评级从 “持有” 上调至 “强烈买入”。三位股票研究分析师对该股给予了强烈买入评级，十三位给予了买入评级，八位给予了持有评级。根据 MarketBeat 的数据，艾伯维目前的共识评级为 “适度买入”，共识目标价为 245.84 美元。</p>
</div><p><strong>Read Our Latest Analysis on ABBV</strong></p>
<div class="lb-trans"><p><strong>阅读我们对艾伯维的最新分析</strong></p>
</div><h2>About AbbVie</h2>
<div class="lb-trans"><h2>关于艾伯维</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.</p>
<div class="lb-trans"><p>艾伯维是一家全球性的、以研究为驱动的生物制药公司，于 2013 年从雅培实验室分拆而成，总部位于伊利诺伊州北芝加哥。该公司专注于发现、开发和商业化针对复杂且常常是慢性医疗条件的治疗方案。其业务涵盖研究与开发、制造、监管事务和商业化，重点是将专业药物推向多个治疗领域的市场。</p>
</div><p>AbbVie's product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women's health.</p>
<div class="lb-trans"><p>艾伯维的产品组合和研发管道涵盖多个主要治疗类别，包括免疫学、肿瘤学、神经科学、病毒学和女性健康。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另见</h2>
</div><ul>
<li>Five stocks we like better than AbbVie</li>
<li>Do not delete, read immediately</li>
<li>INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off</li>
<li>Can Any Expenses Be Deducted From Capital Gains Tax?</li>
<li>Buffett, Gates and Bezos Quietly Dumping Stocks—Here's Why</li>
<li>The Last Gold Bull Market</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票比艾伯维更好</li>
<li>请勿删除，立即阅读</li>
<li>投资者警报：微型 “3 美元人工智能奇迹股票” 即将爆发</li>
<li>是否可以从资本利得税中扣除任何费用？</li>
<li>巴菲特、盖茨和贝索斯悄然抛售股票——原因在这里</li>
<li>最后的黄金牛市</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding ABBV?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他对冲基金持有的艾伯维股票吗？</strong> 请访问 HoldingsChannel.com 获取艾伯维公司（NYSE:ABBV - 免费报告）的最新 13F 文件和内部交易信息。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFCQlY" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=ABBV"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in AbbVie Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在艾伯维吗？</h2>
</div><p>Before you consider AbbVie, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑艾伯维之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AbbVie wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而艾伯维并不在名单上。</p>
</div><p>While AbbVie currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然艾伯维目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Berger Financial Group Inc 在艾伯维公司持有价值 464 万美元的股份